How does 9Y8's PB Ratio compare to its peers?

Insufficient data to calculate 9Y8's Price-To-Book Ratio vs. peers for valuation analysis.

How does 9Y8's PB Ratio compare vs other companies in the DE Biotechs Industry?

Insufficient data to calculate 9Y8's Price-To-Book Ratio vs. industry for valuation analysis.

What is 9Y8's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate 9Y8's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of 9Y8 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate 9Y8's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Oncoinvent DB:9Y8 Stock Report

Last Price

€0.25

Market Cap

€25.0m

7D

-1.6%

1Y

n/a

Updated

20 Jan, 2025

Data

Company Financials

Oncoinvent ASA

DB:9Y8 Stock Report

Market Cap: €25.0m

9Y8 Stock Overview

A clinical stage company, develops products to treat cancer patients. More details

9Y8 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Has not reported any financial data

Shares are highly illiquid

Does not have a meaningful market cap (€294M)

My Notes

Capture your thoughts, links and company narrative

Oncoinvent ASA Competitors

Medigene

XTRA:MDG1

€17.4m

4SC

DB:VSC

€58.9m

2invest

XTRA:2INV

€68.4m

co.don

XTRA:CNW

€6.5m

Price History & Performance

Summary of share price highs, lows and changes for Oncoinvent
Historical stock prices
Current Share Price	NOK 0.25
52 Week High	NOK 0.28
52 Week Low	NOK 0.23
Beta	0
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-3.46%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	9Y8	DE Biotechs	DE Market
7D	-1.6%	-2.1%	3.0%
1Y	n/a	-3.8%	12.8%

Return vs Industry: Insufficient data to determine how 9Y8 performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how 9Y8 performed against the German Market.

Price Volatility

Is 9Y8's price volatile compared to industry and market?
9Y8 volatility
9Y8 Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.2%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.5%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 9Y8's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine 9Y8's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2010	n/a	Oystein Soug	www.oncoinvent.com

Oncoinvent ASA, a clinical stage company, develops products to treat cancer patients. The company’s lead product candidate is Radspherin for the treatment of metastatic cancers in body cavities, as well as peritoneal carcinomatosis for ovarian and colorectal cancers. It also develops antibodies OI-1 (anti-PTK7) and OI-3 (anti-CD146) that are used as targeting modules for radionuclide or drug delivery.

Oncoinvent ASA Fundamentals Summary

How do Oncoinvent's earnings and revenue compare to its market cap?
9Y8 fundamental statistics
Market cap	€25.00m
Earnings (TTM)	€0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is 9Y8 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
9Y8 income statement (TTM)
Revenue	€0
Cost of Revenue	€0
Gross Profit	€0
Other Expenses	€0
Earnings	€0

Last Reported Earnings

n/a

Next Earnings Date

Feb 27, 2025

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did 9Y8 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/20 15:49
End of Day Share Price	2025/01/17 00:00
Earnings	N/A
Annual Earnings	N/A

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Oncoinvent ASA is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution